Awarded a 3-year SBIR phase 2 grant for structure-based drug discovery of dopamine D2 receptor selective ligands.
A high resolution structure of a target GPCR-G protein complex bound to a candidate compound was solved by cryo-EM. On December 2018, an additional GPCR target was added to this collaboration. Several high-resolution structures were delivered by Oct 2019.
Established a collaborative deal with a pharmaceutical company to obtain GPCR structures with proprietary compounds.
Awarded a 5-year SBIR Fast-Track phase 1 & 2 grant for structure based drug discovery of dopamine D1 receptor selective small molecule ligands.
Pain and Addiction: a solution to the opioid epidemic. By Brian Kobilka Watch on YouTube »
ConfometRx unlocks novel GPCR-G protein structure within UCB research collaboration. We are pleased to announce that it has succeeded in elucidating the crystallographic structure of a novel GPCR-G protein complex composed of a Family A GPCR coupled to its G protein, only the second reported GPCR-G protein complex. More »
Awarded a 1-year SBIR phase 1 grant for structure-based drug discovery of dopamine D2 receptor selective ligands.
Awarded a 3-year SBIR phase 1 & 2 grant for Developing Methods in Crystallizing and Drug Discovery for a Family B GPCR.
The structure of A2A Adenosine receptor bound to a novel antagonist was solved in collaboration with UCB Pharma.
ConfometRx Awarded Patent on GPCRs that Contain a Stabilizing IC2 Fusion Protein Read more
ConfometRx and UCB Announce New R&D Partnership. Under this two-year multi-target agreement UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs. More »
Brian Kobilka, co-founder, was awarded the Nobel Prize in Chemistry. His co-recipient is Robert Lefkowitz of Duke University. More »
Awarded a 3-year SBIR phase 2 grant for Developing Methods in Crystallizing a Family C GPCR.
Established a collaboration with Bristol-Myers Squibb Company to obtain crystal structures of a G-protein coupled receptor to enable discovery of novel medicines for unmet medical needs.
The structure of M1 muscarinic receptor bound to an antagonist was solved.
Confometrx signed a multi-year collaborative agreement with Novo Nordisk A/S of Denmark to obtain crystal structures of a GPCR. Combining the extensive expertise of both companies, the goal is to discover newer and better therapeutic agents.
Awarded a 2-year SBIR phase 1 grant for Developing Methods in Crystallizing a Family C GPCR.
Awarded phase 1 SBIR grant for Developing Methods for Crystallizing Family B GPCRs.
Established a multi-year collaboration with Bristol-Myers Squibb Company to obtain crystal structures of G-protein coupled receptors to enable discovery of novel medicines for unmet medical needs.
Signed a collaborative agreement with Lundbeck A/S of Denmark whereby ConfometRx, Inc will obtain crystal structures of two G-protein coupled receptors for Lundbeck A/S. The agreement is based on upfront and milestone payments.
Work on the second target from Medarex was initiated.
Awarded Phase I SBIR Grant to develop a flourescent screening assay based on ConfoTeG technology.
ConfometRx has entered into a partnership with Medarex, Inc. to generate novel immunogens. We are providing Medarex with high-quality protein preparations produced using our proprietary technology for membrane-associated protein expression and purification.